Hims & Hers Stock Plunges 21.3% in 3 Months: Time to Hold or Exit?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 13 2025
0mins
Should l Buy TDOC?
Source: NASDAQ.COM
Stock Performance and Financial Results: Hims & Hers Health, Inc. has faced a decline of 21.3% in stock value recently, underperforming compared to industry peers, despite reporting strong growth in subscribers and online revenue in Q2 2025. The company anticipates significant revenue growth for the upcoming quarters but is challenged by rising product costs affecting gross margins.
Expansion and Strategic Initiatives: The company is expanding its personalized healthcare platform and geographic reach through acquisitions like ZAVA, while also launching new programs such as an affordable weight loss initiative in Canada. Hims & Hers aims to leverage AI for enhanced diagnostics and treatment plans, positioning itself for future growth despite current stock price challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TDOC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TDOC
Wall Street analysts forecast TDOC stock price to rise
15 Analyst Rating
3 Buy
12 Hold
0 Sell
Hold
Current: 5.140
Low
7.50
Averages
8.91
High
12.00
Current: 5.140
Low
7.50
Averages
8.91
High
12.00
About TDOC
Teladoc Health, Inc. provides virtual healthcare services. Its segments include Teladoc Health Integrated Care (Integrated Care) and BetterHelp. Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. Services in this segment are distributed on a B2B basis. BetterHelp segment includes direct-to-consumer mental health platform. The online counseling and therapy services are provided via its network of over 35,000 licensed clinicians leveraging its platform for Web, mobile app, phone, and text-based interactions. Its Teladoc Health family of brands, including Teladoc and BetterHelp, deliver access to advice and resolution for an array of healthcare needs. Its Telecare brand is a tech-enabled provider of specialist and allied health care via virtual delivery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Teladoc Appoints New Board Member, Stock Rises 6%
- New Board Appointment: Teladoc Health announced the appointment of Susan Salka to its board on Monday, who brings 33 years of experience as the former CEO of AMN Healthcare Services, potentially enhancing strategic oversight and governance.
- Stock Price Surge: Following the announcement, Teladoc's stock rose 6% on Tuesday, indicating a positive market reaction to the new board member, which may bolster investor confidence in the company's future prospects.
- Shareholder Pressure: Pineal Capital sent an open letter to Teladoc's board, criticizing the slow pace of action in key areas, which could expose the company to takeover risks, emphasizing a significant disconnect between current stock price and intrinsic value.
- Value Unlocking Strategy: Pineal Capital urged the board to adopt a plan that includes a $200 million+ share buyback program and a strategic review, potentially breaking up Teladoc's two core businesses to enhance cost efficiencies and maximize shareholder value.
See More
Teladoc Health Appoints New Board Member
- New Board Member: Teladoc Health has appointed former AMN Healthcare CEO Susan Salka to its board of directors, effective immediately, aiming to enhance the company's capabilities in healthcare leadership and governance.
- Extensive Industry Experience: With 33 years at AMN Healthcare, where she drove strategic success and grew revenue to over $5 billion, Salka's insights are expected to significantly contribute to Teladoc's transformation in health outcomes.
- Governance Structure Enhancement: Salka will serve on the board's audit and compensation committees, filling vacancies left by the retirements of Eric Evans and Thomas McKinley, thereby optimizing the governance structure to support future growth.
- Strategic Value Creation: Salka emphasized that integrated, outcomes-focused care is central to creating lasting value, and her addition is anticipated to drive innovation and business expansion for Teladoc in the virtual care sector.
See More
Virtual Health Visits Expected to Surge in Coming Decades
- Market Growth Potential: Virtual health visits are expected to see significant growth over the next decade, addressing the increasing demand for telehealth and driving the digital transformation of the healthcare industry.
- Technology-Driven: As technology advances and user acceptance rises, virtual health services will become more widespread, enhancing patient convenience and accessibility to medical services.
- Investment Opportunities: Healthcare institutions and tech companies are likely to increase investments in virtual health platforms to capitalize on this rapidly growing market, which is expected to create new business models and revenue streams.
- Policy Support: Governments and regulatory bodies may introduce more supportive policies to promote the development of virtual health services, further driving the standardization and regulation of the industry.
See More
TELADOC HEALTH: BARCLAYS LOWERS TARGET PRICE FROM $8.5 TO $7
- Barclays Adjusts Price Target: Barclays has lowered its price target for Teladoc Health from $8.5 to $7.
- Market Implications: This adjustment reflects Barclays' updated outlook on Teladoc's performance in the market.
See More
Adobe CEO Resignation Triggers Stock Decline
- Adobe CEO Transition: Adobe's CEO Shantanu Narayen announced his resignation after a successor is named, causing shares to tumble over 5%, despite the company beating first-quarter earnings expectations, indicating market concerns over leadership changes.
- Fertilizer Stocks Retreat: Fertilizer companies' shares fell back due to ongoing disruptions in the Strait of Hormuz, with Intrepid Potash down about 8% and both Mosaic and CF Industries dropping around 4%, reflecting market sensitivity to raw material price fluctuations.
- Ulta Beauty Earnings Miss: Ulta Beauty reported fourth-quarter earnings of $8.01 per share, falling short of the $8.03 expected by analysts, leading to a 12% drop in stock price, despite revenue of $3.9 billion exceeding expectations, highlighting pressures on profitability.
- Once Upon A Farm Performance Decline: Once Upon A Farm reported its first earnings since going public, guiding for 2026 adjusted EBITDA of $2 million to $4 million, significantly lower than $6.6 million in Q4 2025, resulting in an 8% stock drop and raising concerns about future growth prospects.
See More
Hims & Hers Health Shares Drop 7.75% Amid Profit-Taking
- Stock Fluctuation: Hims & Hers Health closed at $23.84 on Thursday, down 7.88%, primarily due to traders taking profits after a strong rally following its partnership with Novo Nordisk, indicating market concerns over the execution of its branded obesity drugs.
- Surge in Trading Volume: The trading volume reached 68 million shares, about 126% above the three-month average of 30 million shares, reflecting heightened market interest in the company's dynamics, and despite the price drop, investors remain focused on its future performance.
- Long-Term Performance Analysis: Despite Thursday's decline, Hims & Hers saw a 50% increase in stock price over the last five trading days, driven by the Novo Nordisk partnership, impressive earnings report, and analyst upgrades, showcasing a strong short-term rebound.
- Legal Risk Warning: Investors should be aware of the legal risks associated with the company's products potentially falling into a gray area around patent protections, particularly as they monitor potential litigation and partnership agreements that could impact the company's long-term growth prospects.
See More
Teladoc Appoints New Board Member, Stock Rises 6%
- New Board Appointment: Teladoc Health announced the appointment of Susan Salka to its board on Monday, who brings 33 years of experience as the former CEO of AMN Healthcare Services, potentially enhancing strategic oversight and governance.
- Stock Price Surge: Following the announcement, Teladoc's stock rose 6% on Tuesday, indicating a positive market reaction to the new board member, which may bolster investor confidence in the company's future prospects.
- Shareholder Pressure: Pineal Capital sent an open letter to Teladoc's board, criticizing the slow pace of action in key areas, which could expose the company to takeover risks, emphasizing a significant disconnect between current stock price and intrinsic value.
- Value Unlocking Strategy: Pineal Capital urged the board to adopt a plan that includes a $200 million+ share buyback program and a strategic review, potentially breaking up Teladoc's two core businesses to enhance cost efficiencies and maximize shareholder value.
See More
Teladoc Health Appoints New Board Member
- New Board Member: Teladoc Health has appointed former AMN Healthcare CEO Susan Salka to its board of directors, effective immediately, aiming to enhance the company's capabilities in healthcare leadership and governance.
- Extensive Industry Experience: With 33 years at AMN Healthcare, where she drove strategic success and grew revenue to over $5 billion, Salka's insights are expected to significantly contribute to Teladoc's transformation in health outcomes.
- Governance Structure Enhancement: Salka will serve on the board's audit and compensation committees, filling vacancies left by the retirements of Eric Evans and Thomas McKinley, thereby optimizing the governance structure to support future growth.
- Strategic Value Creation: Salka emphasized that integrated, outcomes-focused care is central to creating lasting value, and her addition is anticipated to drive innovation and business expansion for Teladoc in the virtual care sector.
See More
Virtual Health Visits Expected to Surge in Coming Decades
- Market Growth Potential: Virtual health visits are expected to see significant growth over the next decade, addressing the increasing demand for telehealth and driving the digital transformation of the healthcare industry.
- Technology-Driven: As technology advances and user acceptance rises, virtual health services will become more widespread, enhancing patient convenience and accessibility to medical services.
- Investment Opportunities: Healthcare institutions and tech companies are likely to increase investments in virtual health platforms to capitalize on this rapidly growing market, which is expected to create new business models and revenue streams.
- Policy Support: Governments and regulatory bodies may introduce more supportive policies to promote the development of virtual health services, further driving the standardization and regulation of the industry.
See More
TELADOC HEALTH: BARCLAYS LOWERS TARGET PRICE FROM $8.5 TO $7
- Barclays Adjusts Price Target: Barclays has lowered its price target for Teladoc Health from $8.5 to $7.
- Market Implications: This adjustment reflects Barclays' updated outlook on Teladoc's performance in the market.
See More
Adobe CEO Resignation Triggers Stock Decline
- Adobe CEO Transition: Adobe's CEO Shantanu Narayen announced his resignation after a successor is named, causing shares to tumble over 5%, despite the company beating first-quarter earnings expectations, indicating market concerns over leadership changes.
- Fertilizer Stocks Retreat: Fertilizer companies' shares fell back due to ongoing disruptions in the Strait of Hormuz, with Intrepid Potash down about 8% and both Mosaic and CF Industries dropping around 4%, reflecting market sensitivity to raw material price fluctuations.
- Ulta Beauty Earnings Miss: Ulta Beauty reported fourth-quarter earnings of $8.01 per share, falling short of the $8.03 expected by analysts, leading to a 12% drop in stock price, despite revenue of $3.9 billion exceeding expectations, highlighting pressures on profitability.
- Once Upon A Farm Performance Decline: Once Upon A Farm reported its first earnings since going public, guiding for 2026 adjusted EBITDA of $2 million to $4 million, significantly lower than $6.6 million in Q4 2025, resulting in an 8% stock drop and raising concerns about future growth prospects.
See More
Hims & Hers Health Shares Drop 7.75% Amid Profit-Taking
- Stock Fluctuation: Hims & Hers Health closed at $23.84 on Thursday, down 7.88%, primarily due to traders taking profits after a strong rally following its partnership with Novo Nordisk, indicating market concerns over the execution of its branded obesity drugs.
- Surge in Trading Volume: The trading volume reached 68 million shares, about 126% above the three-month average of 30 million shares, reflecting heightened market interest in the company's dynamics, and despite the price drop, investors remain focused on its future performance.
- Long-Term Performance Analysis: Despite Thursday's decline, Hims & Hers saw a 50% increase in stock price over the last five trading days, driven by the Novo Nordisk partnership, impressive earnings report, and analyst upgrades, showcasing a strong short-term rebound.
- Legal Risk Warning: Investors should be aware of the legal risks associated with the company's products potentially falling into a gray area around patent protections, particularly as they monitor potential litigation and partnership agreements that could impact the company's long-term growth prospects.
See More
